Brokerages Set Genmab A/S Sponsored ADR (NASDAQ:GMAB) Price Target at $40.58

Genmab A/S Sponsored ADR (NASDAQ:GMAB) has received a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $40.5833.

Several analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Genmab A/S from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. HC Wainwright raised their price target on shares of Genmab A/S from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Morgan Stanley started coverage on shares of Genmab A/S in a report on Monday, February 16th. They set an “equal weight” rating and a $34.00 price target on the stock. Guggenheim reduced their price objective on shares of Genmab A/S from $45.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, February 23rd. Finally, Wells Fargo & Company assumed coverage on shares of Genmab A/S in a research note on Monday, March 2nd. They issued an “overweight” rating and a $40.00 price objective for the company.

Genmab A/S Stock Performance

Shares of Genmab A/S stock opened at $26.36 on Friday. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $35.43. The company has a quick ratio of 2.01, a current ratio of 2.02 and a debt-to-equity ratio of 0.86. The business has a 50 day moving average price of $30.70 and a 200-day moving average price of $30.56. The company has a market cap of $16.94 billion, a PE ratio of 17.01, a price-to-earnings-growth ratio of 1.09 and a beta of 0.94.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Tuesday, February 17th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.46 by ($0.41). The company had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.06 billion. Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%. Equities analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

A number of institutional investors and hedge funds have recently modified their holdings of GMAB. Founders Capital Management boosted its position in Genmab A/S by 40.0% in the fourth quarter. Founders Capital Management now owns 1,400 shares of the company’s stock worth $43,000 after purchasing an additional 400 shares during the last quarter. Parallel Advisors LLC increased its position in shares of Genmab A/S by 11.3% during the 3rd quarter. Parallel Advisors LLC now owns 4,139 shares of the company’s stock valued at $127,000 after purchasing an additional 419 shares during the last quarter. CWM LLC raised its stake in shares of Genmab A/S by 18.8% during the 4th quarter. CWM LLC now owns 2,739 shares of the company’s stock worth $84,000 after purchasing an additional 433 shares during the period. Jones Financial Companies Lllp boosted its holdings in shares of Genmab A/S by 29.1% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,951 shares of the company’s stock worth $57,000 after buying an additional 440 shares during the last quarter. Finally, Osaic Holdings Inc. boosted its holdings in shares of Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after buying an additional 440 shares during the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.